RxDoctor Payments Data

Joanne Kim, MD

Neurology · Houston, TXNPI 1922048644

Payments from drug & device makers

$29,674in general payments, 2019–2025

Across 363 payments — averaging $81.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
  • AbbVie$1K
  • UCB, Inc.$569
  • SK Life Science, Inc.$523
  • Lilly USA, LLC$437
  • Eisai Inc.$388
  • plus $6K from 51 others
$1,679in research payments, 2019–2025

Across 7 payments — averaging $239.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K

What the payments were for

  • Speaking & faculty fees$561%
  • Food & beverage$8,46999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka Pharmaceutical Development & Commercialization, Inc.2$21,150
AbbVie(2 entities)57$1,084
UCB, Inc.23$569
SK Life Science, Inc.20$523
Lilly USA, LLC19$437
Eisai Inc.13$388
Pfizer19$364
Teva Pharmaceuticals USA, Inc.12$352
Acadia Pharmaceuticals Inc18$351
Johnson & Johnson5$313
Novartis14$266
Amgen9$235
Supernus Pharmaceuticals, Inc.11$203
Boston Scientific4$199
Biogen11$191
Abbott3$171
Otsuka America Pharmaceutical, Inc.9$170
Lundbeck LLC7$158
Medtronic(2 entities)4$154
Amneal Pharmaceuticals LLC9$151
Genentech USA, Inc.8$149
Novo Nordisk3$144
Bausch Health US, LLC8$140
Neurocrine Biosciences, Inc.4$131
E.r. Squibb & Sons, L.L.C.1$124
Biohaven Pharmaceuticals, Inc.1$124
EMD Serono, Inc.6$108
Paratek Pharmaceuticals, Inc.1$96
Avanir Pharmaceuticals, Inc.6$94
Kyowa Kirin, Inc.4$92
Upsher-smith Laboratories LLC4$85
Jazz Pharmaceuticals Inc.3$76
GE HealthCare2$75
Adamas Pharmaceuticals, Inc.3$74
Sanofi4$70
Assertio Therapeutics, Inc.4$65
AstraZeneca3$63
Acorda Therapeutics, Inc3$56
Axsome Therapeutics, Inc.2$48
Scilex Pharmaceuticals Inc.2$39
Mallinckrodt Hospital Products Inc.1$34
Impel Pharmaceuticals Inc.2$32
Insightec,inc3$30
Currax Pharmaceuticals LLC2$29
Neurelis, Inc.1$29
Grifols USA, LLC1$27
Avion Pharmaceuticals1$24
Arbor Pharmaceuticals, Inc.2$24
Biohaven Pharmaceutical Holding Company Ltd.1$23
Argenx US, Inc.1$22
Azurity Pharmaceuticals, Inc.1$21
Impel Pharmaceuticals LLC1$20
Kowa Pharmaceuticals America, Inc.1$19
Corium, LLC1$19
Aprecia Pharmaceuticals, LLC1$17
Vertical Pharmaceuticals, LLC1$15
Aucta Pharmaceuticals, Inc.1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,674 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$208,240
Medicare patients
649
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa22$38,815
RexultiBrexpiprazole18$36,870
Nurtec OdtRimegepant Sulfate19$34,405
Rasagiline Mesylate75$18,034
Memantine Hcl498$14,713
VimpatLacosamide20$13,732
Emgality PenGalcanezumab-Gnlm18$13,438
DilantinPhenytoin Sodium Extended22$9,519
Memantine Hcl ErMemantine Hcl69$8,010
Galantamine ErGalantamine Hbr75$7,428
RivastigmineRivastigmine Tartrate118$6,705
Donepezil Hcl320$6,131
Gabapentin298$4,512
Carbidopa-LevodopaCarbidopa/Levodopa189$4,319
Lacosamide29$4,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$364$43,92441 claims
Amneal Pharmaceuticals LLCRytary$151$38,81522 claims
Otsuka America Pharmaceutical, Inc.Rexulti$170$36,87018 claims
UCB, Inc.Vimpat$569$13,73220 claims
Upsher-smith Laboratories LLCTopiramate$85$89752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →